TY - JOUR AU - Kantarjian, H; Cortes, J; Kim, D-W TI - Phase 3 study of Dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up JO - Blood IS - 25 VL - 113 PY - 2009 DO - 10.1182/blood-2008-11-186817 L3 - PubMed-ID: 19369231 SP - 6322 EP - 6329 ER -